Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Discontinued
Reference number: GID-TA11318
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late May 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late July 2024.
These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.